With Luke Miels in place as chief executive, GSK Plc is taking steps to simplify operations and identify new opportunities in its late-stage pipeline. A portfolio review is underway to identify 50 promising assets that could be the focus of drug development in the coming years. Mr Miels became CEO on 1 January, succeeding Emma Walmsley. He had previously been the company’s chief commercial officer having joined GSK in 2017.
UCB SA announced on 3 May that it has signed an agreement to acquire Candid Therapeutics Inc of San Diego, US, broadening its portfolio to include biologics targeting autoimmune and inflammatory diseases. The Belgium-based biopharma company already has marketed products for epilepsy, plaque psoriasis, and Crohn’s disease. The acquisition will add preclinical and early clinical-stage products to UCB’s portfolio, the most advanced of which are bispecific T cell engagers. These are antibodies that can bind T cells to tumour cells to kill cancers.
AstraZeneca Plc expects revenue this year to grow by a mid-to-high single-digit percentage as label expansions for existing drugs and new molecular entities progress towards market entry. At a briefing for journalists on 29 April, Pascal Soriot, the chief executive, confirmed the company’s ambition to achieve revenue of $80 billion by 2030. He said the company is advancing through a “catalyst-rich period” with multiple positive Phase 3 readouts and regulatory submissions underway.
Preparing for the next pandemic
The role of real-world data in medical care
Venture debt as an option for start-up companies
Kailera taps IPO market for obesity
Gilead to acquire Tubulis
Q1 resilient with signs of recovery continuing
Early warnings for Parkinson's disease
